Risk of invasive fungal infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: A TriNetX-based retrospective cohort study from 2000-2025. Propensity ...

The U.S. Food and Drug Administration has approved Taiho Oncology's Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) ...

Venetoclax shows potential in pediatric relapsed/refractory AML/MDS, with a 41.6% overall response rate and 33% complete response rate in a single-center study. Combining venetoclax with cytotoxic ...

SAN DIEGO -- Patients with relapsed/refractory mantle cell lymphoma (MCL) lived significantly longer without disease progression with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta ...

Stergiou said the delayed timeline for reaching the final event trigger has increased optimism for the Regal trial. ・The CEO also disclosed that some Regal patients remain on treatment more than three ...

The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible ...

Shorter-duration venetoclax may be as effective as longer-duration treatment in AML and MDS, with no significant impact on overall survival. The study included 53 patients, predominantly male, with a ...

Venetoclax (Venclexta) shows promise as salvage therapy for patients with relapsed or refractory hairy cell leukemia (HCL), according to a small study in which five of six patients responded to the ...

Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd., today announced that the U.S. Food and Drug Administration (FDA) has ...

Forbes contributors publish independent expert analyses and insights. I cover cancer science, treatments and attitudes. Why I like about Venetoclax is that it derives from science, and that it works.

Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase ...